Clinical Trials Logo
  1. Home
  2. GIST
  3. NCT05734105

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib — INSIGHT  

GIST Clinical Trial

Official title:
An International, Phase 3, Randomized, Multicenter, Open-label Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated With Imatinib

Clinical Trial Summary

This is a Phase 3, 2-arm, randomized, open-label, global, multicenter study comparing the efficacy of ripretinib to sunitinib in participants with GIST who progressed on first-line treatment with imatinib, harbor co-occurring KIT exons 11+17/18 mutations, and are without KIT exon 9, 13, or 14 mutations. Upon disease progression as determined by an independent radiologic review, participants randomized to sunitinib will be given the option to either crossover to receive ripretinib 150 mg QD or discontinue sunitinib.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05734105
Study type Interventional
Source Deciphera Pharmaceuticals LLC
Contact Clinical Team
Phone 785-830-2100
Email Clinicaltrials@deciphera.com
Status Recruiting
Phase Phase 3
Start date December 13, 2023
Completion date December 2027
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05957367 - A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies Phase 1/Phase 2
Completed NCT01770405 - Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract N/A
Active, not recruiting NCT03556384 - Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST) Phase 2
Recruiting NCT05895942 - Exploring the Molecular Mechanism Based on KIT Mutation
Completed NCT01459757 - Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib N/A
Completed NCT00979381 - Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor N/A
Completed NCT00399152 - Perifosine + Sunitinib Malate for Patients With Advanced Cancers Phase 1
Recruiting NCT03715933 - Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Phase 1
Completed NCT04599660 - Study in Low Risk Gastrointestinal Stromal Tumor (GISTs)
Completed NCT05400018 - Clinical Evaluation of Genetron D842V PCR Kit in GIST Patients
Recruiting NCT03475953 - A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04825470 - Liver Transplantation for Unresectable GIST Liver Metastases N/A
Recruiting NCT00687778 - 11C-Acetate PET/CT Non-FDG-Avid Tumors N/A
Completed NCT00979329 - Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST N/A
Active, not recruiting NCT04927260 - French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients
Completed NCT03465722 - (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST Phase 3
Completed NCT03880617 - Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy
Recruiting NCT03896958 - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Completed NCT01323400 - Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) Phase 2
Recruiting NCT05804331 - The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study